Targeting prostate cancer cells with enzalutamide‐HDAC inhibitor hybrid drug 2‐75
Abstract
The progression of castration‐resistant prostate cancer (CRPC) still relies on the function of androgen receptor (AR), achieved by evolving mechanisms to reactivate AR signaling under hormonal therapy. Histone deacetylase inhibitors (HDACis) disrupt cytoplasmic AR chaperone heat shock protein 90 (Hsp90) via HDAC6 inhibition, leading to AR degradation and growth suppression of prostate cancer (PCa) cells. However, current HDACis are not effective in clinical trials treating CRPC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 28, 2019
- Source ID
- 10.1002/pros.23832
Entities
People
- Bailing Chen
- Dan‐ping Hu
- Donald J Vander Griend
- Gail S. Prins
- Kendall M. Muzzarelli
- Liping Xu
- Siyu Ou
- Wen‐yang Hu
- Ye Li
- Zhe Yang
- Zhihui Qin
Organizations
- United States Department of Defense
- University of Illinois at Chicago
- Wayne State University